All CALML3 reagents are produced in house and quality controlled, including 5 CALML3 Antibody, 2 CALML3 Gene, 1 CALML3 IPKit, 1 CALML3 Protein, 1 CALML3 qPCR. All CALML3 reagents are ready to use.
Recombinant CALML3 proteins are expressed by E. coli with fusion tags as N-His.
CALML3antibodies are validated with different applications, which are WB, ELISA, IHC-P, IP, FCM, ICC/IF, IF.
CALML3cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CALML3 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
Calmodulin-like protein 3 (CALML3) is similar to that of authentic calmodulin and may actually compete with calmodulin by binding, with different affinity, to cellular substrates. Calmodulin-like protein 3 (CALML3) is a tumor-sensitive protein specifically expressed in normal epithelial cells but downregulated in tumorigenesis. Downregulation of the protein is an early event in breast cancer development. One of the most pressing questions raised by the discovery of CLP/CALML3 is that of its potential targets. Although it is 85% identical to human calmodulin, the distinct properties of CLP suggest that it has specific targets or targets that only partially overlap with those of calmodulin. Research has identified the unconventional myosin-10 (Myo10) as a specific target of CALML3. The discovery of Myo10 as a specific target of CALML3 is highly significant and suggests multiple lines of further research such as investigations of the Ca2+ regulation of Myo10 and the role of the loss of CLP in epithelial differentiation, adhesion, and cancer. Cells expressing CALML3 displayed a striking increase in the number and length of myosin-10-positive filopodia and showed increased mobility in a wound healing assay.